Gurugram-based Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60000 sq. ft. in Jhajjar, Haryana. The next-generation unit is expected to be operational by mid of 2026.
The facility is designed to serve customers with science-baked, derma-driven, wellness products. The company has made a massive investment of Rs 70 crore and is proud to be a part of the government backed ‘Make-in-India’ movement.
This unit is equipped with best-in-class control systems and equipment. The facility will be supported by an experienced team that will be committed to ensuring large-scale commercial manufacturing is carried on smoothly. The scale of manufacturing will not compromise on international standards of quality control. The plant will focus on delivering economically viable solutions, in a robust, compliant, and environmentally sustainable manner. The idea is to support customers who are seeking highly effective, and personalised skin-care products.
Overall, with a focus on research and development, the high-tech research laboratories will support continuous tracking of market, consumer demand, product development, and judicious formulation improvement, all of which will be grounded in real-world science.
At full scale, this manufacturing unit will make more than 12 million units a year in the areas of dermatology, wellness and chronic care for the Indian and global markets. The company will also generate 600+ jobs in this facility.
Iberia Pharmaceuticals brings clinically tested, globally trusted brands to Indian consumers, including Sesderma, Mediderma, Dermpix, Noreva, Metacare amongst other respected brands.
